Protocol Ledger

NCT06268574 · Phase II · TERMINATED

Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML

Interventional Phase II clinical trial protocol NCT06268574 sponsored by Ryvu Therapeutics SA in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-01-23 Enrollment: 62 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06268574
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)62 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06268574
Protocol FieldVerified Registry Value
NCT IdentifierNCT06268574
Consolidated Lead SponsorRyvu Therapeutics SA
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment62 participants (ACTUAL)
Registered Start Date2024-01-23
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06268574
Hospital Research SiteLocationSite Profile
ASST Grande Ospedale Metropolitano NiguardaMilan, ItalyOpen Hospital Dossier ->
Azienda Ospedaliero Universitaria PisanaPisa, ItalyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI